...
首页> 外文期刊>BMC Genomics >Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood
【24h】

Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood

机译:三种用于宏基因组测序和血液中病原体鉴定的下一代测序平台的比较

获取原文
           

摘要

Background The introduction of benchtop sequencers has made adoption of whole genome sequencing possible for a broader community of researchers than ever before. Concurrently, metagenomic sequencing (MGS) is rapidly emerging as a tool for interrogating complex samples that defy conventional analyses. In addition, next-generation sequencers are increasingly being used in clinical or related settings, for instance to track outbreaks. However, information regarding the analytical sensitivity or limit of detection (LoD) of benchtop sequencers is currently lacking. Furthermore, the specificity of sequence information at or near the LoD is unknown. Results In the present study, we assess the ability of three next-generation sequencing platforms to identify a pathogen (viral or bacterial) present in low titers in a clinically relevant sample (blood). Our results indicate that the Roche-454 Titanium platform is capable of detecting Dengue virus at titers as low as 1X102.5 pfu/mL, corresponding to an estimated 5.4X104 genome copies/ml maximum. The increased throughput of the benchtop sequencers, the Ion Torrent PGM and Illumina MiSeq platforms, enabled detection of viral genomes at concentrations as low as 1X104 genome copies/mL. Platform-specific biases were evident in sequence read distributions as well as viral genome coverage. For bacterial samples, only the MiSeq platform was able to provide sequencing reads that could be unambiguously classified as originating from Bacillus anthracis. Conclusion The analytical sensitivity of all three platforms approaches that of standard qPCR assays. Although all platforms were able to detect pathogens at the levels tested, there were several noteworthy differences. The Roche-454 Titanium platform produced consistently longer reads, even when compared with the latest chemistry updates for the PGM platform. The MiSeq platform produced consistently greater depth and breadth of coverage, while the Ion Torrent was unequaled for speed of sequencing. None of the platforms were able to verify a single nucleotide polymorphism responsible for antiviral resistance in an Influenza A strain isolated from the 2009 H1N1 pandemic. Overall, the benchtop platforms perform well for identification of pathogens from a representative clinical sample. However, unlike identification, characterization of pathogens is likely to require higher titers, multiple libraries and/or multiple sequencing runs.
机译:背景技术台式测序仪的引入使全基因组测序的应用成为可能,这一领域的研究者比以往任何时候都更为广泛。同时,宏基因组测序(MGS)迅速兴起,成为询问复杂样品的一种工具,该方法违背了常规分析方法。另外,下一代定序器正越来越多地用于临床或相关场合,例如,以追踪疾病暴发。但是,目前缺乏有关台式测序仪的分析灵敏度或检测限(LoD)的信息。此外,在LoD处或附近的序列信息的特异性是未知的。结果在本研究中,我们评估了三个下一代测序平台识别临床相关样品(血液)中低滴度的病原体(病毒或细菌)的能力。我们的结果表明,Roche-454 Titanium平台能够以低至1X10 2.5 pfu / mL的滴度检测登革热病毒,相当于估计的5.4X10 4 基因组拷贝/ ml最大值。台式测序仪,Ion Torrent PGM和Illumina MiSeq平台的通量提高,可检测低至1X10 4 基因组拷贝/ mL浓度的病毒基因组。平台特异性偏差在序列读取分布以及病毒基因组覆盖率方面很明显。对于细菌样品,只有MiSeq平台能够提供测序读数,这些读数可以明确地归类为来自炭疽芽胞杆菌。结论三种平台的分析灵敏度均接近标准qPCR分析的灵敏度。尽管所有平台都能够以测试水平检测病原体,但仍存在一些值得注意的差异。即使与PGM平台的最新化学更新相比,Roche-454 Titanium平台也能产生更长的读数。 MiSeq平台始终具有更大的覆盖深度和广度,而离子激流在测序速度方面无与伦比。没有一个平台能够验证从2009年H1N1大流行中分离出的甲型流感病毒株中引起抗病毒耐药性的单核苷酸多态性。总体而言,台式平台在从代表性临床样品中鉴定病原体方面表现良好。但是,与鉴定不同,病原体的表征可能需要更高的滴度,多个文库和/或多个测序运行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号